Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4383 | autologous adipose-derived stem cells Wiki | 1.00 |
| drug2729 | Oseltamivir Wiki | 0.38 |
| drug421 | Azithromycin Wiki | 0.16 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Novel Coronavirus (2019nCoV) or Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) that causes Coronavirus Disease 2019, or known as Covid-19 has recently become a global health emergency since it was first detected in Wuhan, the People Republic of China in December 2019. Since then, the prevalence has rapidly increased worldwide. In Indonesia, by the end of April 2020, around 10,000 patients have been tested positive for Covid-19 infection, with a case fatality rate of around 8%. The pathogenesis of Covid-19 is still under investigation and to our understanding, ACE2 receptors in the alveoli serve as the binding site of the S-protein of envelope spike virus of SARS-CoV-2. TMPRSS2 enzyme aids the fusion between cell membrane and capsid of the virus, allowing penetration of virus into the cell. Vesicles containing virion fuse with cell membrane and released as new virions. Cytopathic effect of the virus and its ability to overcome immune response determines the degree of infection. Differences in immunological profile among degrees of severity of Covid-19 may vary especially for the number of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-1, IL-6, IL-8, leukemia-inhibiting factors (LIF), immunological markers such as CXCR3+CD4+, CXCR3+CD8+ T cell and CXCR3+ NK cells, implying the ongoing cytokine storm. The previous studies also found increasing number for infection markers such as procalcitonin, ferritin, and C-reactive protein. The decreasing number of anti-inflammatory cytokines in such as IL-10 also supports this finding. Previous studies have shown immunomodulating and anti-inflammatory capacity of the mesenchymal stem cells (MSCs). MSCs contributed to the shifting of pro-inflammatory Th2 into anti-inflammatory Th2. One of the most recent study on the usage of MSCs on Covid-19 patients showed increased expression of leukemia inhibitory factor (LIF), which give rise to inhibitory effect of T lymphocyte and natural killer (NK) cell population. Vascular epithelial growth factor (VEGF) is found increasing following MSCs administration, which indicates the ability to improve the disrupted capillaries due to SARS-Cov-2 infection. The ability of MSCs in differentiating to alveolar cells is proven by the presence of SPM and SPC2, surfactant proteins produced by type II alveolar cells. MSCs are unable to be infected by SARS-CoV-2 since they don't have ACE2 receptors and TMPRSS2 enzyme.
Description: Assessing whether the patients still have dyspnea, one of cardinal symptoms of Covid-19, assessed from the respiratory rate
Measure: Clinical improvement: Presence of dyspnea Time: 15 daysDescription: Assessing whether the patients still have productive cough, one of cardinal symptoms of Covid-19, assessed from lung auscultation
Measure: Clinical improvement: presence of sputum Time: 15 daysDescription: Assessing the presence of fever from measurement of body temperature checking, assessed on daily basis
Measure: Clinical improvement: fever Time: 15 daysDescription: Assessing whether the patients still require ventilation, one of cardinal symptoms of ARDS in Covid-19, assessed from patients' ability during ventilation weaning phase
Measure: Clinical improvement: ventilation status Time: 15 daysDescription: Assessing the patients' blood pressure on daily basis
Measure: Clinical improvement: blood pressure Time: 15 daysDescription: Assessing the patients' heart rate on daily basis
Measure: Clinical improvement: heart rate Time: 15 daysDescription: Assessing the patients' respiratory rate on daily basis
Measure: Clinical improvement: respiratory rate Time: 15 daysDescription: Assessing the patients' oxygen saturation on daily basis
Measure: Clinical improvement: oxygen saturation Time: 15 daysDescription: Assessing the changes in total leukocyte upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from leukocyte level Time: 15 daysDescription: Assessing the changes in lymphocytes level upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from lymphocytes level Time: 15 daysDescription: Assessing the changes in blood pH level upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from blood pH Time: 15 daysDescription: Assessing the changes in blood pH level upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from blood level of CO2 Time: 15 daysDescription: Assessing the changes in blood base excess level upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from blood base excess level Time: 15 daysDescription: Assessing the changes in blood oxygen partial pressure upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from blood oxygen partial pressure Time: 15 daysDescription: Assessing the changes in blood level of HCO3 upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from blood level of HCO3 Time: 15 daysDescription: Assessing the changes in blood level of O2 saturation upon MSCs administration, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from blood level of O2 saturation Time: 15 daysDescription: Assessing the changes in level of CRP, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from level of CRP Time: 15 daysDescription: Assessing the changes in laboratory parameter, consist of SGOT/SGPT (AST/ALT) level, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from level of SGOT/SGPT (AST/ALT) Time: 15 daysDescription: Assessing the changes in laboratory parameter, consist of ureum/creatinine level, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from the level of ureum/creatinine level Time: 15 daysDescription: Assessing the changes in laboratory parameter, consist of eGFR, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from the level of eGFR Time: 15 daysDescription: Assessing the changes in level of sodium, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from the level of sodium Time: 15 daysDescription: Assessing the changes in level of potassium, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from the level of potassium Time: 15 daysDescription: Assessing the changes in level of chloride, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from the level of chloride Time: 15 daysDescription: Assessing the changes in procalcitonin level to assess the anti-inflammatory properties of MSCs, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: Changes in procalcitonin level Time: 15 daysDescription: Assessing the changes in albumin level, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from albumin level Time: 15 daysDescription: Assessing the changes in total bilirubin level, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: General laboratory outcome from total bilirubin level Time: 15 daysDescription: Assessing the changes in D-Dimer to assess the anti-inflammatory properties of MSCs, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: Changes in D-Dimer level Time: 15 daysDescription: Assessing the changes in fibrinogen to assess the anti-inflammatory properties of MSCs, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: Changes in fibrinogen level Time: 15 daysDescription: Assessing the changes in troponin level to assess the anti-inflammatory properties of MSCs and their effect in cardiac remodelling, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: Cardiac changes from troponin level Time: 15 daysDescription: Assessing the changes in NT proBNP to assess the anti-inflammatory properties of MSCs and their effect in cardiac remodelling, assessed prior to and 1st day after implantation, then once every 3 days post implantation
Measure: Cardiac changes from NT proBNP level Time: 15 daysDescription: Assessing the changes in leukemia inhibiting factor (LIF) to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation
Measure: Changes in Leukemia Inhibiting Factor Time: 7 daysDescription: Assessing the changes in level of IL-6 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation
Measure: Changes in level of IL-6 Time: 7 daysDescription: Assessing the changes in level of IL-10 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation
Measure: Changes in level of IL-10 Time: 7 daysDescription: Assessing the changes in vascular endothelial growth factor (VEGF) to assess the effect of growth factors in the MSCs, assessed prior to implantation and on the 7th day post-implantation
Measure: Changes in level of vascular endothelial growth factor (VEGF) Time: 7 daysDescription: Assessing the changes in level of ferritin to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation
Measure: Changes in level of ferritin Time: 7 daysDescription: Assessing the changes in level of CXCR3 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation
Measure: Changes in level of CXCR3 Time: 7 daysDescription: Assessing the changes in level of CD4 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation
Measure: Changes in level of CD4 Time: 7 daysDescription: Assessing the changes in level of CD8 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation
Measure: Changes in level of CD8 Time: 7 daysDescription: Assessing the changes in CD56 to assess the anti-inflammatory properties of MSCs, assessed prior to implantation and on the 7th day post-implantation
Measure: Changes in level of CD56 Time: 7 daysDescription: Assessing the changes in radiology examination (Chest X-Ray/CT Scan) for any increased in lung infiltration or ground glass opacity, assessed prior to implantation and once every 3 days post-implantation
Measure: Radiologic Improvement from Chest X-Ray/CT Scan Time: 15 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports